Fabry Disease | A Pipeline Analysis Report 2018 | Technavio | Financial Buzz

Fabry Disease | A Pipeline Analysis Report 2018 | Technavio

Technavio
has announced their latest pipeline analysis report on the Fabry
disease market. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat Fabry disease.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180623005070/en/

Technavio has published a new report on the drug development pipeline for Fabry disease, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

Fabry disease: Market overview

Fabry disease is a lipid-metabolism disorder or lysosomal storage
disorder, is a rare genetic disease, which is inherited in an X-linked
pattern. This disorder can lead to a deficiency of alpha-galactosidase A
enzyme. Alpha-galactosidase A breaks glycolipids ( a combination of
sugar and lipid molecules).

According to a senior analyst at Technavio for infectious and rare
diseases, “In a few glycolipid molecules such as
globotriaosylceramide (GL-3 or Gb3), lyso-GL-3/Gb3, and related
glycolipids. The alpha-galactosidase A enzyme removes the terminal
galactose sugar from the end of these glycolipid molecules.”

Fabry disease segmentation

This market research report segments the fabry disease market based on
therapies employed that includes monotherapy, combination therapy, and
unknown, RoA (IV, oral, and unknown), therapeutic modalities (small
molecules, biological, gene therapy, and unknown), targets for drugs
under development (alpha-galactosidase, alpha-galactosidase A,
glucosylceramide synthase, BET, and unknown), drugs under development
(pre-clinical, phase I, phase I/II, phase II, phase III, and
pre-registration), MoA (alpha-galactosidase replacement,
alpha-galactosidase stimulator, glucosylceramide synthase inhibitor,
alpha-galactosidase A inhibitor, BET inhibitor, gene transference, and
unknown), and recruitment status (recruiting, completed, active not
recruiting, not yet recruiting, and unknown). It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180623005070/en/